Intellia Therapeutics (NTLA) Equity Average (2016 - 2026)
Intellia Therapeutics (NTLA) reported Equity Average of $646.2 million for Q1 2026, down 21.77% year-over-year from $825.9 million in Q1 2025, and down 8.98% on a QoQ basis from $709.9 million in Q4 2025.
Intellia Therapeutics (NTLA) has 11 years of Equity Average data on file, last reported at $646.2 million in Q1 2026.
- Quarterly Equity Average fell 21.77% year-over-year to $646.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $646.2 million (down 21.77% YoY) and the FY2025 annual result came in at $771.7 million, down 19.71% from the prior year.
- Equity Average retreated to $646.2 million in Q1 2026 per NTLA's latest filing, from $709.9 million in the prior quarter.
- Across five years, Equity Average topped out at $1.2 billion in Q1 2023 and bottomed at $646.2 million in Q1 2026.
- The 5-year median for Equity Average is $966.8 million (2024), against an average of $933.3 million.
- The widest annual swing landed in 2022, when Equity Average surged 85.84%; it then declined 25.51% in 2025.
- Tracing NTLA's Equity Average over 5 years: stood at $1.0 billion in 2022, then climbed by 1.31% to $1.0 billion in 2023, then fell by 12.12% to $917.3 million in 2024, then declined by 22.61% to $709.9 million in 2025, then fell by 8.98% to $646.2 million in 2026.
- Per Business Quant, the three latest NTLA Equity Average figures stand at $646.2 million (Q1 2026), $709.9 million (Q4 2025), and $731.8 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 3.76 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 21.35 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 19.01 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 31.34 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 932.28 Mn |
| 10 | Intellia Therapeutics | 1.63 Bn | 1.63 Bn | - | 646.17 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 646.17 Mn |
| Dec 31, 2025 | 709.91 Mn |
| Sep 30, 2025 | 731.84 Mn |
| Jun 30, 2025 | 747.59 Mn |
| Mar 31, 2025 | 825.94 Mn |
| Dec 31, 2024 | 917.29 Mn |
| Sep 30, 2024 | 966.84 Mn |
| Jun 30, 2024 | 1.00 Bn |
| Mar 31, 2024 | 1.04 Bn |
| Dec 31, 2023 | 1.04 Bn |
| Sep 30, 2023 | 1.07 Bn |
| Jun 30, 2023 | 1.15 Bn |
| Mar 31, 2023 | 1.21 Bn |
| Dec 31, 2022 | 1.03 Bn |
| Sep 30, 2022 | 852.75 Mn |
| Jun 30, 2022 | 917.15 Mn |
| Mar 31, 2022 | 997.00 Mn |
| Dec 31, 2021 | 1.07 Bn |
| Sep 30, 2021 | 800.96 Mn |
| Jun 30, 2021 | 520.34 Mn |
| Mar 31, 2021 | 536.47 Mn |
| Dec 31, 2020 | 428.35 Mn |
| Sep 30, 2020 | 340.60 Mn |
| Jun 30, 2020 | 299.67 Mn |
| Mar 31, 2020 | 258.82 Mn |
| Dec 31, 2019 | 272.77 Mn |
| Sep 30, 2019 | 276.26 Mn |
| Jun 30, 2019 | 270.60 Mn |
| Mar 31, 2019 | 271.13 Mn |
| Dec 31, 2018 | 270.60 Mn |
| Sep 30, 2018 | 271.30 Mn |
| Jun 30, 2018 | 287.42 Mn |
| Mar 31, 2018 | 298.05 Mn |
| Dec 31, 2017 | 238.22 Mn |
| Sep 30, 2017 | 181.72 Mn |
| Jun 30, 2017 | 193.73 Mn |
| Mar 31, 2017 | 204.86 Mn |
| Dec 31, 2016 | 213.98 Mn |
| Sep 30, 2016 | 220.86 Mn |
| Jun 30, 2016 | 98.23 Mn |
| Mar 31, 2016 | -24.17 Mn |